Trial · NCT07579962
Treatment of Low-flow Vascular Malformations With Bleomycin Electrosclerotherapy (BEST)
NCT07579962, Phase 2, Recruiting, Institute of Oncology Ljubljana
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Low-flow Vascular Malformations With Bleomycin Electrosclerotherapy (BEST). Trials, record NCT07579962. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07579962
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Low-flow Vascular Malformations With Bleomycin Electrosclerotherapy (BEST)
- NCT number
- NCT07579962
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 140 participants, estimated
- Lead sponsor
- Institute of Oncology Ljubljana
- Conditions
- Vascular Malformations
- Interventions
- Bleomycin Sulfate
- First posted
- 2026-05-12
- Last updated
- 2026-10-09
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MRI-measured mean change in lesion volume from baseline to 3 months after BEST treatment | Baseline and 3 months after treatment | Lesion volume will be assessed by magnetic resonance imaging at baseline and 3 months after treatment. Lesion volume will be calculated from MRI images using the ellipsoid formula: a x b x c x π/6. The outcome measure will report the mean change in lesion volume from baseline to 3 months after BEST treatment. |
| Secondary | MRI-measured mean change in lesion volume from baseline to 12 months after BEST treatment | Baseline and 12 months after treatment | Lesion volume will be assessed by magnetic resonance imaging at baseline and 12 months after treatment. Lesion volume will be calculated from MRI images using the ellipsoid formula: a x b x c x π/6. The outcome measure will report the mean change in lesion volume from baseline to 12 months after BEST treatment. |
| Secondary | Number of participants who complete protocol-defined BEST treatment and follow-up visits | Up to 12 months after treatment | Feasibility will be assessed by the number of participants who complete the protocol-defined BEST treatment and scheduled follow-up visits at 3 months and 12 months after treatment. |
| Secondary | Number of participants with treatment-emergent adverse events as assessed by CTCAE version 5.0 | Up to 12 months after treatment | Treatment-emergent adverse events will be recorded, classified according to MedDRA terminology, graded using CTCAE version 5.0, and assessed for relationship to the investigational medicinal product or procedure. |
| Secondary | Change in quality of life from baseline to 3 and 12 months after BEST treatment as assessed by the OVAMA questionnaire | Baseline, 3 months, and 12 months after treatment | Quality of life will be assessed using the OVAMA questionnaire at baseline, 3 months, and 12 months after treatment. The outcome measure will report the change in OVAMA questionnaire results from baseline to 3 and 12 months after BEST treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07579962
GET https://conductscience.org/api/trials/v1/NCT07579962/registered